Jump to content

Covid-19: Razvoj vakcine, imunitet i primena medikamenata

bey
bey
in Covid-19 Coronavirus

Featured Replies

 

Danas kažu ovde da testiranja Novavaksove vakcine dobro napreduju, ako se nastavi ovim tempom možda bude dostupna oko Nove godine:

 

...

The data – published on a pre-print site and not yet peer-reviewed – appears promising, but the findings are too preliminary to draw firm conclusions about how effective it may be at protecting the public from the COVID-19 virus SARS-CoV-2 and curbing the pandemic.

 

The trial tested the Novavax vaccine candidate NVX-CoV2373 in a trial of 130 heath volunteers in Melbourne and Brisbane who received varying doses of the vaccine or a placebo.

 

Participants who received two doses of the vaccine three weeks apart had neutralising antibody levels roughly four times higher than a group of 32 patients who had recovered from COVID-19.

...

The vaccine uses synthesised pieces of the surface protein of the coronavirus created in the laboratory that enables the virus to invade human cells, triggering the body's immune response by way of the production of antibodies to fight off the infection.

...

Participants were given 5 microgram and 25 microgram doses of the vaccine, with and without the adjuvant. Novavax said it would likely move forward with the lower dose.

 

Among participants given two doses of the vaccine, roughly 80 per cent had pain and tenderness at the site of the injection. Overall, just over 60 per cent of participants had other side effects, the majority mild to moderate and most commonly headache, fatigue and muscle pain.

 

Eight trial participants experienced adverse side effects after receiving a second vaccine that was deemed "severe". None required hospitalisations. All side effects resolved in a few days.

 

Overall the vaccine was extremely well tolerated and had a very good safety profile, Dr Gregory Glenn said.

...

 

SaE

cini se da su druge vakcine imale manje burne nuspojave u fazi 1.

Ako nuspojave budu ovakve, niko se više neće vakcinisati ubuduće. 

Putin doakao Gejtsu, zato laze SZO.

 

image.png.72e1cf9658a5ac28978c1bcc864521e5.png

Sa testiranom ciljnom grupom od 38 osoba. Kvalitetno.

Sent from my VOG-L29 using Tapatalk

hide GIF

 

“The registration of the vaccine developed at the Gamelei Center will take place on August 12,” Gridnev told journalists in Ufa on Friday morning, as cited by RIA Novosti. “Now the last stage, the third, is underway. This is the testing part and is extremely important. We have to understand that the vaccine itself must be safe.”

 

tek treba da odrade trecu fazu. oksfordska i moderna su na istom stadijumu razvoja, zapravo i kineske isto.

Edited by precog

zar nisu oxford i kina vec poceli trecu fazu ? rusi tek treba da pocnu.

 

nije mi jasno zasto se to predstavlja kao da je gotova, u njihovom slucaju

1 minute ago, Tsai said:

zar nisu oxford i kina vec poceli trecu fazu ? rusi tek treba da pocnu.

 

nije mi jasno zasto se to predstavlja kao da je gotova, u njihovom slucaju

u pravu si, trebalo bi da su vec poceli regrutaciju za trecu fazu. a ova vest je mislim vise hmmm, pa recimo za prestiz.

Pa ti posle ne veruj u stereotipe

Pa normalno kad im dobro ide suzbijanje virusa, pa su prestali da se brinu :fantom:

Go to topic listing